Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Palvella Therapeutics, Inc. Common Stock

PVLA

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Last trade $142.20
Day change -$2.405 (-1.66%)
Day range $140.77 – $147.57
Volume 129,184
Market cap $2.11B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.11B
Price / earnings
—
Price / book
10.68×
Price / sales
—
EV / sales
—
EV / EBITDA
-27.32×

Profitability

Earnings per share
-$5.13
Return on assets
-31.33%
Return on equity
-37.89%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
16.01×
Quick ratio
16.01×
Cash ratio
12.95×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$43.06M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PVLA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$11.9M$8.93M$5.52M$4.18M$3.65M$4.13M$3.8M$1.82M
Research and development$10.82M$12.47M$9.33M$7.12M$6.53M$5.12M$4.07M$2.54M
Total operating expenses$22.73M$21.41M$14.86M$11.3M$10.18M$9.25M$7.87M$4.37M
Operating income-$22.73M-$21.41M-$14.86M-$11.3M-$10.18M-$9.25M-$7.87M-$4.37M
Interest expense-$2.81M-$2.31M-$2.04M-$1.74M-$1.51M-$1.35M-$1.22M-$1.3M
Income before taxes-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$3.95M
Income taxes$0$0$0$0$0$0$0$0
Net income-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$3.95M
Net income attributable to common shareholders-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$3.37M
EBITDA-$22.73M-$21.41M-$14.86M-$11.3M-$10.18M-$9.25M-$7.87M-$4.37M
Basic earnings per share-$1.70-$1.52-$1.20-$1.07-$1.03-$0.86-$0.74-$0.94
Diluted earnings per share-$1.70-$1.52-$1.20-$1.07-$1.03-$0.86-$0.74-$0.94

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally

Palvella Therapeutics' Chief Operating Officer Kathleen Goin sold 4,302 shares worth $476,000 through a pre-planned trading arrangement, while retaining 17,219 options. The sale comes amid a 620% one-year stock surge driven by investor optimism about the company's QTORIN rapamycin therapy for rare skin diseases. The FDA recently granted rolling review for the drug's New Drug Application, with the company targeting NDA completion in H2 2026.

The Motley Fool

Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal

Palvella Therapeutics' COO Kathleen Goin sold 4,302 shares worth ~$508,000 on March 18, 2026, through a pre-planned Rule 10b5-1 trading plan adopted in August. The sale should not raise concerns as it was a structured liquidity event tied to option exercises. The stock has surged 340% over the past year, supported by positive Phase 3 results for its lead candidate QTORIN rapamycin (95% of participants showed improvement), a planned New Drug Application submission in H2 2026, and a recent $230 million equity offering.

Benzinga

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Palvella Therapeutics (NASDAQ: PVLA) closed its upsized public offering on February 27, 2026, raising $230.0 million in gross proceeds by selling 1,840,000 shares at $125.00 per share, including the full exercise of underwriters' option for 240,000 additional shares. The company plans to use the net proceeds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations.

GlobeNewswire Inc.

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Palvella Therapeutics priced an upsized public offering of 1.6 million shares at $125 per share, raising $200 million in gross proceeds before underwriting costs. The clinical-stage biopharmaceutical company plans to use the funds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations. The offering is expected to close on February 27, 2026.

GlobeNewswire Inc.

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics announced it will host a conference call on February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations. The company plans to release results at 6:30am ET prior to the call.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.